Breakwater
Title
An open-label, multicenter, randomized phase 3 study of first-line Encorafenib plus Cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of Encorafeniband Cetuximab plus chemotherapyin participants with metastatic BRAF V600E-mutant colorectal cancer
Trial ID
NCT04607421
Cancer type
Colorectal cancer with specific changes in the genes of the cancer (BRAF V600E)
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.